{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:22:41Z","timestamp":1779916961065,"version":"3.53.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ivermectin (Mectizan) is an anthelmintic drug that plays a major role in the fight against two major filarial diseases, onchocerciasis and lymphatic filariasis. Unlike previous drugs that had serious and sometimes fatal side effects, ivermectin has been considered to be safe and, therefore, is widely used. Data reporting the clinical presentation of poisoning with ivermectin are very scanty, even in experimental studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>In this paper, we report the case of a 19-year-old Black African female student residing in Obala (Centre Region, Cameroon) who was admitted to a health facility in Central Cameroon for a neurological disorder after intoxication with about 400 tablets of ivermectin 3\u00a0mg (~100 times the standard doses). This neurological disorder was characterized by somnolence, kinetic ataxia, increase of tendon reflex, and central visual disturbance. Management of this intoxication consisted of symptomatic treatment and monitoring of hemodynamic parameters for 5\u00a0days, with a favorable course.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This is the first report of a poisoning with\u2009ivermectin at ~100 times the recommended dose. This case report confirms the safety and tolerability of ivermectin, even at exceptionally high dose.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-023-03891-4","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:01:42Z","timestamp":1681689702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Successful management of poisoning with ivermectin (Mectizan) in the Obala health district (Centre Region, Cameroon): a case report"],"prefix":"10.1186","volume":"17","author":[{"given":"Cyrille","family":"Donfo-Azafack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4496-6048","authenticated-orcid":false,"given":"Hugues C.","family":"Nana-Djeunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Wafeu-Sadeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00efssa","family":"Dongmo-Yemele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kamgno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"key":"3891_CR1","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.6308762","volume":"221","author":"WC Campbell","year":"1983","unstructured":"Campbell WC, Fisher MH, Stapley EO, Albers-Schonberg G, Jacob TA. Ivermectin: a potent new antiparasitic agent. Science. 1983;221:823\u20138.","journal-title":"Science"},{"key":"3891_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0151-9638(04)93668-X","volume":"131","author":"M Develoux","year":"2004","unstructured":"Develoux M. Ivermectine. Ann Dermatol Venereol. 2004;131:561\u201370.","journal-title":"Ann Dermatol Venereol"},{"issue":"11","key":"3891_CR3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.pt.2005.08.014","volume":"21","author":"TG Geary","year":"2005","unstructured":"Geary TG. Ivermectin 20 years on: maturation of a wonder drug. Trends Parasitol. 2005;21(11):530\u20132.","journal-title":"Trends Parasitol"},{"issue":"Suppl 1","key":"3891_CR4","first-page":"S46","volume":"92","author":"BA Boatin","year":"1998","unstructured":"Boatin BA, Hougard JM, Alley ES, Akpoboua LK, Yameogo L, Dembele N, Seketeli A, Dadzie KY. The impact of Mectizan on the transmission of onchocerciasis. Ann Trop Med Parasitol. 1998;92(Suppl 1):S46-60.","journal-title":"Ann Trop Med Parasitol"},{"issue":"8313","key":"3891_CR5","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/S0140-6736(82)91350-2","volume":"2","author":"MA Aziz","year":"1982","unstructured":"Aziz MA, Diallo S, Lariviere M, Diop IM, Porta IM, Gaxotte P. Ivermectin in onchocerciasis. Lancet. 1982;2(8313):1456\u20137.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"3891_CR6","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1186\/1475-2883-2-S1-S7","volume":"2","author":"NA Twum-Danso","year":"2003","unstructured":"Twum-Danso NA. Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future. Filaria J. 2003;2(Suppl 1):S7.","journal-title":"Filaria J"},{"key":"3891_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0140-6736(96)11094-1","volume":"350","author":"J Gardon","year":"1997","unstructured":"Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 1997;350:18\u201322.","journal-title":"Lancet"},{"issue":"4","key":"3891_CR8","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/jac\/dkz524","volume":"75","author":"M Navarro","year":"2020","unstructured":"Navarro M, Camprub\u00ed D, Requena-M\u00e9ndez A, Buonfrate D, Giorli G, Kamgno J, Gardon J, Boussinesq M, Mu\u00f1oz J, Krolewiecki A. Safety of high-dose ivermectin: a systematic review and meta-analysis. J Antimicrob Chemother. 2020;75(4):827\u201334.","journal-title":"J Antimicrob Chemother"},{"key":"3891_CR9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1177\/009127002237994","volume":"42","author":"CA Guzzo","year":"2002","unstructured":"Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, Sciberras DG, Hsieh JYK, Lasseter KC. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002;42:1122\u201333.","journal-title":"J Clin Pharmacol"},{"key":"3891_CR10","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/bcp.13840","volume":"85","author":"U Duthaler","year":"2019","unstructured":"Duthaler U, Suenderhauf C, Karlsson MO, Hussner J, Schwabedissen HM, Kr\u00e4henb\u00fchl S, Hammann F. Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers. Br J Clin Pharmacol. 2019;85:626\u201333.","journal-title":"Br J Clin Pharmacol"},{"key":"3891_CR11","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1292\/jvms.10-0424","volume":"73","author":"SM Trailovic","year":"2011","unstructured":"Trailovic SM, Nedeljkovic JT. Central and peripheral neurotoxic effects of ivermectin in rats. J Vet Med Sci. 2011;73:591\u20139.","journal-title":"J Vet Med Sci"},{"key":"3891_CR12","first-page":"33","volume":"80","author":"JD Pulliam","year":"1985","unstructured":"Pulliam JD, Seward SR, Henry RT, Steinberg SA. Investigating ivermectin toxicity in collies. Vet Med. 1985;80:33\u201340.","journal-title":"Vet Med"},{"key":"3891_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.trstmh.2004.04.003","volume":"99","author":"G Fobi","year":"2005","unstructured":"Fobi G, Gardon J, Kamgno J, Aimard-Favennec L, Lafleur C, Gardon-Wendel N, Duke BOL, Boussinesq M. A randomized, double-blind, controlled trial of the effects of ivermectin at normal and high doses, given annually or three-monthly, against Onchocerca volvulus: ophthalmological results. Trans R Soc Trop Med Hyg. 2005;99:279\u201389.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"3891_CR14","first-page":"1","volume":"3","author":"M Patte","year":"2006","unstructured":"Patte M, Sillaire I, Pauchard E, Coulangeon LM, Kantelip B, Bacin F. Barri\u00e8res h\u00e9mato-oculaires. Physiologie. 2006;3:1\u201312.","journal-title":"Physiologie"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-03891-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-023-03891-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-03891-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:01:47Z","timestamp":1681689707000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-023-03891-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3891"],"URL":"https:\/\/doi.org\/10.1186\/s13256-023-03891-4","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,17]]},"assertion":[{"value":"22 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried out as part as the routine surveillance of severe adverse events occurring post-ivermectin treatments against onchocerciasis and lymphatic filariasis. The follow-up of the patient was therefore approved by, and undertaken under the authority of the Ministry of Public Health. Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal. Data were presented anonymously.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}